Alnylam Pharmaceuticals, Inc. (ALNY) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 30.04B USD. 52-week range 197.81 to 495.55 USD. Trailing P/E 37.9. Data as of 2026-10-09.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products ...